- Home
- RDNW vs IKT Comparison
RDNW vs IKT Comparison
Compare RDNW & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDNW
- IKT
- Stock Information
- Founded
- RDNW 2013
- IKT 2008
- Country
- RDNW United States
- IKT United States
- Employees
- RDNW N/A
- IKT N/A
- Industry
- RDNW EDP Services
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- RDNW Technology
- IKT Health Care
- Exchange
- RDNW Nasdaq
- IKT Nasdaq
- Market Cap
- RDNW 147.3M
- IKT 140.5M
- IPO Year
- RDNW N/A
- IKT 2020
- Fundamental
- Price
- RDNW $3.83
- IKT $1.66
- Analyst Decision
- RDNW
- IKT Buy
- Analyst Count
- RDNW 0
- IKT 2
- Target Price
- RDNW N/A
- IKT $8.00
- AVG Volume (30 Days)
- RDNW 2.1M
- IKT 97.5K
- Earning Date
- RDNW 08-11-2025
- IKT 08-14-2025
- Dividend Yield
- RDNW N/A
- IKT N/A
- EPS Growth
- RDNW N/A
- IKT N/A
- EPS
- RDNW N/A
- IKT N/A
- Revenue
- RDNW $1,109,200,000.00
- IKT N/A
- Revenue This Year
- RDNW N/A
- IKT N/A
- Revenue Next Year
- RDNW $7.73
- IKT N/A
- P/E Ratio
- RDNW N/A
- IKT N/A
- Revenue Growth
- RDNW N/A
- IKT N/A
- 52 Week Low
- RDNW $1.46
- IKT $1.12
- 52 Week High
- RDNW $7.06
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- RDNW N/A
- IKT 45.73
- Support Level
- RDNW N/A
- IKT $1.66
- Resistance Level
- RDNW N/A
- IKT $1.87
- Average True Range (ATR)
- RDNW 0.00
- IKT 0.10
- MACD
- RDNW 0.00
- IKT -0.01
- Stochastic Oscillator
- RDNW 0.00
- IKT 33.82
About RDNW RideNow Group Inc. Class B Common Stock
RideNow Group Inc is a USA-based online retailer that allows consumers and dealers both to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.